References
- Bates SM, Weitz JI. (2006). The status of new anticoagulants. Br J Haematol, 134, 3–19.
- Bin Wu, Licheng, Wu, Daijie Chen, Zhijun, Yang, Minyu Luo. (2009). Purification and characterization of a novel fibrinolytic protease from Fusarium sp. CPCC 480097. J Ind Microbiol Biot, 36, 451–459.
- Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248–254.
- Butenas S, Mann KG. (2002). Blood coagulant. Biochemistry, 67, 5–15.
- Chu AJ, Beydoun S, Mathews ST, Hoang JL. (2003). Novel anticoagulant polyethylenimine: Inhibition of thrombin-catalyzed fibrin formation. Arch Biochem Biophys, 415, 101–108.
- Dahlbäck B. (2000). Blood coagulation. Lancet, 355, 1627–1632.
- Drouet L. (1996). Fibrinogen: A treatable risk factor? Cerebrovasc Dis, 6, 2–6.
- Frizzell JP. (2005). Acute stroke: Pathophysiology, diagnosis, and treatment. AACN Clin Issues, 16, 421–40.
- Guglielmone HA, Agnese AM, Núñez Montoya SC, Cabrera JL. (2002). Anticoagulant effect and action mechanism of sulphated flavonoids from Flaveria bidentis. Thromb Res, 105, 183–188.
- Hirsh J. (2003). Current anticoagulant therapy–unmet clinical needs. Thromb Res, 109, 1–8.
- Howard SC, Algra A, Rothwell PM; (2008) Cerebrovascular cohort studies collaboration. Effect of age and glycaemic control on the association between fibrinogen and risk of acute coronary events after transient ischaemic attack or stroke. Cerebrovasc Dis, 25, 136–143.
- Kannel WB. (1997). Influence of fibrinogen on cardiovascular disease. Drugs, 54, 32–40.
- Kim MS, Lee KA. (2006). Antithrombotic activity of methanolic extract of Umbilicaria esculenta. J Ethnopharmacol, 105, 342–345.
- Maksimenko AV, Tischenko EG, Golubykh VL. (1999). Antithrombotic activity of the superoxide dismutase-chondroitin sulfate complexes in a rat model of arterial injury. Cardiovasc Drugs Ther, 13, 479–484.
- Motoyashiki T, Tu AT, Azimov DA, Ibragim K. (2003). Isolation of anticoagulant from the venom of tick, Boophilus calcaratus, from Uzbekistan. Thromb Res, 110, 235–241.
- Nutescu EA. (2003). The future of anticoagulation clinics. J Thromb Thrombolysis, 16, 61–63.
- Peng X, Huang WY. (2004). Clinical analysis of defibrase injection in treatment of acute cerebral infarction. China J Mod Med, 14, 36–38.
- Philomene WK, Masao Y, Katsushito A, Chinzei Y. (1998). Purification and characterization of a thrombin inhibitor from the salivary glands of a malarial vector mosquito, Anopheles stephensi. Biochim Biophys Acta, 1381, 227–233.
- Rosenberg RD, Rosenberg JS. (1984). Natural anticoagulant mechanisms. J Clin Invest, 74, 1–6.
- Rothwell PM, Howard SC, Power DA. (2004). The cerebrovascular cohort studies collaboration: Fibrinogen concentration and risk of ischaemic stroke and acute coronary events in 5113 patients with transient ischaemic attack and minor ischaemic stroke. Stroke, 35, 2300–2305.
- Tanne D, Benderly M, Goldbourt U. (2001). The bezafibrate infarction prevention study group: A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med, 111, 457–463.
- Vlachopoulos C, Pietri P, Aznaouridis K, Vyssoulis G, Vasiliadou C, Bratsas A, Tousoulis D, Xaplanteris P, Stefanadi E, Stefanadis C. (2007). Relationship of fibrinogen with arterial stiffness and wave reflections. J Hypertens, 25, 2110–2116.
- Voet D, Voet JG. (1990). Biochemistry. New York; Wiley; pp 87–1095.
- Von Clauss A. (1957). Rapid physiological coagulant method in determination of fibrinogen. Acta Haematol, 17, 237–244.
- Weitz JI. (2001). New anticoagulant drugs. J Thromb Thrombolysis, 12, 7–17.
- Zingali RB, Jandrot-Perrus M, Guillin MC, Bon C. (1993). Bothrojaracin, a new thrombin inhibitor isolated from Bothrops jararaca venom: Characterization and mechanism of thrombin inhibition. Biochemistry, 32, 10794–10802.